UCB LICENSES SEPRACOR U.S. PATENTS FOR ANTIHISTAMINE.
Under a separate agreement, Sepracor currently earns royalties from UCB on sales of levocetirizine in European countries where the product is sold. Levocetirizine is marketed by UCB under the brand names XYZAL and XUSAL(TM) in the European Union for treatment of symptoms of seasonal and perennial allergic rhinitis, persistent allergic rhinitis, and chronic idiopathic urticaria (CIU, also known as hives of unknown cause) in adults and children aged 6 years and older.
"Sepracor is pleased to extend its licensing arrangement for levocetirizine to the United States. UCB has built a successful antihistamine franchise worldwide and we are optimistic about the opportunity UCB has to expand it with the introduction of levocetirizine in the U.S.," stated Timothy J. Barberich, chairman and CEO of Sepracor.
"We are very excited about our new licensing relationship with Sepracor in the United States and the prospect of expanding our antihistamine business," stated Roch Doliveux, CEO of UCB.
UCB is a global biopharmaceutical company dedicated to the research, development and commercialization of innovative pharmaceuticals and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology - UCB focuses on securing a leading position in severe disease categories. Employing 8,500 people in over 40 countries, UCB achieved revenues of EUR 2.1 billion (including net sales, royalties, and fees) in 2004. UCB is listed on the Euronext Brussels Exchange (UCB / UCBBt.BR / UCB BB) with a market capitalization of approximately EUR 5.8 billion. Worldwide headquarters are located in Brussels, Belgium.
For more information, visit http://www.ucb-group.com.
Sepracor Inc. is a research-based pharmaceutical company dedicated to treating and preventing human disease through the discovery, development and commercialization of innovative pharmaceutical products that are directed toward serving unmet medical needs. Sepracor's drug development program has yielded an extensive portfolio of pharmaceutical compound candidates with a focus on respiratory and central nervous system disorders. Sepracor's corporate headquarters are located in Marlborough, Massachusetts.
For more information, call 508/481-6700
|Printer friendly Cite/link Email Feedback|
|Comment:||UCB LICENSES SEPRACOR U.S. PATENTS FOR ANTIHISTAMINE.|
|Date:||Apr 1, 2006|
|Previous Article:||RENEURON REPORTS REN004 DATA PROMISING FOR PARKINSON'S.|
|Next Article:||CHIRON GETS PANDEMIC INFLUENZA VACCINE CONTRACT WITH U.K.|
|UCB SELLS OTC DELSYM TO ADAMS RESPIRATORY THERAPEUTICS.|
|UCB GETS POSITIVE RESULTS FROM TWO CIMIZIA PHASE III STUDIES.|
|UCB INITIATES ADDITIONAL SHORT-TERM CLINICAL STUDY OF CIMZIA.|